LONDON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS)
("Compass"), a biotechnology company dedicated to accelerating patient access to
evidence-based innovation in mental health, and Hackensack Meridian Health
("HMH"), a leading not-for-profit health care organization and the largest, most
comprehensive and truly integrated network in New Jersey, today announced that
that they have entered into a research collaboration agreement to inform the
delivery model design of investigational COMP360 psilocybin treatment, if FDA-
approved.
The collaboration between Compass and HMH aims to improve health outcomes and
improve patient and provider experiences for mental health conditions such as
treatment-resistant depression. Together they will work to understand the real-
world challenges and opportunities of delivering care to those living with
depression, to inform how future clinical trials of COMP360 psilocybin treatment
are designed, and to understand how it will be delivered to patients, if
approved. COMP360 is Compass's investigational proprietary formulation of
synthetic psilocybin, administered in conjunction with psychological support.
Hackensack Meridian Health offers a complete range of medical services,
innovative research and life-enhancing care. The network has 18 hospitals and
more than 500 patient care locations. The network's notable distinctions include
having the only #1 ranked adult and children's hospitals in New Jersey, as
ranked by U.S. News & World Report, 2023-24. Hackensack University Medical
Center is nationally-ranked by U.S. News & World Report in six specialties.
"We're proud to collaborate with Compass Pathways, a leading biotechnology
company aiming to create real change for people suffering with some of the most
difficult-to-treat mental health conditions," said Robert C. Garrett, FACHE, CEO
of Hackensack Meridian Health. "Our network's leadership in mental health and
extensive experience in treating depression in clinical practice will inform how
new mental health treatments may be accessed by patients in the future."
"Our collaboration with Hackensack Meridian Health will help us understand how
investigational COMP360 psilocybin treatment, if approved, could be delivered to
patients, and represents another important milestone in our mission to provide
better treatment options for people who urgently need them," said Kabir Nath,
CEO of Compass Pathways. "As one of the largest, most comprehensive and truly
integrated health care networks in the US, with a strong mission to improve
clinical outcomes and transform healthcare delivery, HMH is a great
collaboration partner for Compass."
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to
accelerating patient access to evidence-based innovation in mental health. Our
focus is on improving the lives of those who are suffering with mental health
challenges and who are not helped by current treatments. We are pioneering the
development of a new model of psilocybin treatment, in which our proprietary
formulation of synthetic psilocybin, COMP360, is administered in conjunction
with psychological support. COMP360 has been designated a Breakthrough Therapy
by the U.S. Food and Drug Administration (FDA) and has received Innovative
Licensing and Access Pathway (ILAP) designation in the UK for treatment-
resistant depression (TRD).
We have commenced a phase 3 clinical program of COMP360 psilocybin treatment in
TRD, the largest randomized, controlled, double-blind psilocybin treatment
clinical program ever conducted. Previously, we completed a phase 2b study with
top line data showing a statistically significant (pÂ